Some of the key players in the Clear Cell Ovarian Cancer Market include Clovis, Xencor, Genelux Corporation, and some others involved in developing drugs for Clear Cell Ovarian Cancer. The launch of potential emerging therapies such CYH33, (Haihe Biopharma), Serabelisib (Faeth Therapeutics), and XmAb20717 (Xencor) are expected to change the treatment outlook in the upcoming years.
DelveInsight’s “Clear Cell Ovarian Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Clear Cell Ovarian Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Clear Cell Ovarian Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Clear Cell Ovarian Cancer: An Overview
Ovarian clear cell carcinoma (OCCC) is the second most common subtype after high-grade serous carcinoma (HGSC). Clear cell carcinoma of the ovary is a rare and distinct histotype of epithelial ovarian carcinomas. Women diagnosed with clear cell carcinomas are usually younger and diagnosed at earlier stages than those with the most common high-grade serous histology.
These tumors typically arise in middle-aged to older adults as a unilateral mass with an average size of approximately 10 cm. The biology and clinical behavior of OCCC is distinct from other EOCs. OCCC has a unique genetic profile characterized by frequent ARID1A and PIK3CA mutations, MET amplification, and rare p53 mutation.
Clear Cell Ovarian Cancer Market Key Facts
-
The rate of new cases of ovarian cancer was 11.2 per 100,000 women per year. The death rate was 6.7 per 100,000 women per year. These rates are age-adjusted and based on 2013–2017 cases and 2014–2019 deaths.
-
In 2018, there were an estimated 235,081 women living with ovarian cancer in the United States. (Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovary Cancer. National Cancer Institute, 2020)
-
The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being diagnosed. For ovarian cancer, 15.7% are diagnosed at the local stage. The 5-year relative survival for localized ovarian cancer is 92.6%.
Clear Cell Ovarian Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Clear Cell Ovarian Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Clear Cell Ovarian Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Clear Cell Ovarian Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Clear Cell Ovarian Cancer Epidemiology, Segmented as –
-
Total Incident Cases of Ovarian Cancer in the 7MM (2019-32)
-
Mutation-specific Incident Cases of Clear Cell Ovarian Cancer in the 7MM (2019-32)
-
Stage-specific Incident Cases of Clear Cell Ovarian Cancer in the 7MM (2019-32)
-
Diagnosed and Treatable Cases of Clear Cell Ovarian Cancer in the 7MM (2019-32)
Clear Cell Ovarian Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Clear Cell Ovarian Cancer market or expected to be launched during the study period. The analysis covers the Clear Cell Ovarian Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Clear Cell Ovarian Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Clear Cell Ovarian Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/clear-cell-ovarian-cancer-market
Clear Cell Ovarian Cancer Therapeutics Market
The Leading Players in the Clear Cell Ovarian Cancer Therapeutics Market Include:
-
Genentech
-
GlaxoSmithKline
-
AstraZeneca
-
Clinigen Group
-
Novartis
-
Clovis Oncology
-
Ortho Biotech
-
Bristol-Myers Squibb
And Many Others.
Clear Cell Ovarian Cancer Emerging Marketed Drugs Covered in the Report Include:
-
Avastin (bevacizumab): Genentech
-
Zejula (niraparib): GlaxoSmithKline
-
Rubraca: Clovis Oncology
-
Lynparza: AstraZeneca
-
Ethyol (amifostine): Clinigen Group
-
Hycamtin (topotecan hydrochloride): Novartis
-
Doxil: Ortho Biotech
-
Paraplatin: Bristol-Myers Squibb
-
Rucaparib: Clovis
-
Olvimulogene nanivacirepvec (Olvi-Vec): Genelux Corporation
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/clear-cell-ovarian-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Clear Cell Ovarian Cancer Competitive Intelligence Analysis
4. Clear Cell Ovarian Cancer Market Overview at a Glance
5. Clear Cell Ovarian Cancer Disease Background and Overview
6. Clear Cell Ovarian Cancer Patient Journey
7. Clear Cell Ovarian Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Clear Cell Ovarian Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Clear Cell Ovarian Cancer Unmet Needs
10. Key Endpoints of Clear Cell Ovarian Cancer Treatment
11. Clear Cell Ovarian Cancer Marketed Products
12. Clear Cell Ovarian Cancer Emerging Drugs and Latest Therapeutic Advances
13. Clear Cell Ovarian Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Clear Cell Ovarian Cancer Market Outlook (In US, EU5, and Japan)
16. Clear Cell Ovarian Cancer Access and Reimbursement Overview
17. KOL Views on the Clear Cell Ovarian Cancer Market
18. Clear Cell Ovarian Cancer Market Drivers
19. Clear Cell Ovarian Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/clear-cell-ovarian-cancer-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/